Bristol Myers Squibb disclosed mixed Phase 3 results for its idiopathic pulmonary fibrosis therapy admilparant, with only the lower dose meeting the trial’s main objective—intensifying questions about the program’s commercial path in a crowded IPF landscape. In separate Phase 3 reporting, a lung cancer brain-metastasis trial found stereotactic radiosurgery nearly doubled median survival in small cell lung cancer patients (17.4 months vs 8.6 months) without a cognitive downside, reinforcing radiosurgery’s role where local control is the priority. The two updates underscore how payers and prescribers are likely to scrutinize both efficacy consistency and safety tradeoffs as companies line up post-patent products and next-generation combinations.